The stock's intraday low of Rs.78.02 represents a notable underperformance relative to its sector, which outpaced Alpa Laboratories by 3.78% on the day. This decline comes despite the broader market's upward momentum, with the Sensex closing near its 52-week high at 85,218.78 points, just 0.08% shy of the peak level of 85,290.06.
Alpa Laboratories is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward pressure on the stock price. This technical positioning reflects the stock's ongoing challenges in regaining investor confidence.
Over the past year, Alpa Laboratories has recorded a return of -32.45%, a stark contrast to the Sensex's positive performance of 9.85% during the same period. The stock's 52-week high was Rs.137.40, highlighting the extent of the recent decline.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- Expert-scrutinized selection
- Already delivering results
- Monthly focused approach
Financially, Alpa Laboratories has exhibited subdued performance metrics. The company’s operating profit has shown a negative annual rate of change of -206.03% over the last five years, indicating a contraction in core profitability. The latest quarterly results for September 2025 reveal a PAT (Profit After Tax) of Rs.0.11 crore, which is down by 98.3% compared to the previous four-quarter average.
Additionally, the company reported a PBDIT (Profit Before Depreciation, Interest and Taxes) of Rs.-2.24 crore for the quarter, marking one of its lowest levels. The Return on Capital Employed (ROCE) for the half-year stands at 12.57%, which is relatively modest within the sector context.
Alpa Laboratories’ EBITDA has been negative, contributing to the perception of risk associated with the stock. Over the past year, profits have declined by 10.4%, further underscoring the financial pressures faced by the company. This contrasts with the broader BSE500 index, which has generated returns of 8.23% over the same period, highlighting Alpa Laboratories’ underperformance relative to the market.
On the balance sheet front, the company maintains a low average Debt to Equity ratio of zero, indicating minimal reliance on debt financing. The majority shareholding remains with promoters, which may influence strategic decisions and capital allocation.
Holding Alpa Laboratories from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- Peer comparison ready
- Superior options identified
- Cross market-cap analysis
Despite the broader market rally led by mega-cap stocks, Alpa Laboratories has not mirrored this positive trend. The Sensex’s 50-day moving average remains above its 200-day moving average, signalling a bullish market environment that contrasts with the stock’s current trajectory.
The divergence between Alpa Laboratories’ stock performance and the overall market indices highlights the challenges faced by the company within the Pharmaceuticals & Biotechnology sector. The stock’s current valuation and financial indicators suggest a cautious stance among market participants.
In summary, Alpa Laboratories’ fall to a 52-week low of Rs.78.02 reflects a combination of subdued financial results, negative profit trends, and technical weakness. While the broader market and sector indices have shown resilience, the stock continues to face headwinds that have kept it below key moving averages and contributed to its underperformance over the past year.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
